4/17
04:19 pm
npce
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]
Low
Report
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024 [Yahoo! Finance]
4/17
04:05 pm
npce
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
Low
Report
NeuroPace to Report First Quarter 2024 Financial Results on May 8, 2024
3/27
04:05 pm
npce
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
Medium
Report
NeuroPace to Present at the Needham 23rd Annual Healthcare Conference
3/21
02:43 pm
npce
Revamp Medical Announces Appointment of Mike Favet as CEO [Yahoo! Finance]
Neutral
Report
Revamp Medical Announces Appointment of Mike Favet as CEO [Yahoo! Finance]
3/14
08:30 am
npce
NeuroPace, Inc. (NASDAQ: NPCE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $16.00.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $20.00 price target on the stock, up previously from $16.00.
3/11
04:40 am
npce
Neuroprosthetics Market to Reach $26.12 Billion by 2030, Says Coherent Market Insights [Yahoo! Finance]
Medium
Report
Neuroprosthetics Market to Reach $26.12 Billion by 2030, Says Coherent Market Insights [Yahoo! Finance]
3/7
12:03 pm
npce
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
NeuroPace, Inc. (NASDAQ:NPCE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/7
05:26 am
npce
NeuroPace Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
Low
Report
NeuroPace Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
3/6
12:35 pm
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Morgan Stanley from $9.00 to $13.00. They now have an "equal weight" rating on the stock.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Morgan Stanley from $9.00 to $13.00. They now have an "equal weight" rating on the stock.
3/6
12:35 pm
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Cantor Fitzgerald from $16.00 to $18.00. They now have an "overweight" rating on the stock.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Cantor Fitzgerald from $16.00 to $18.00. They now have an "overweight" rating on the stock.
3/5
04:10 pm
npce
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million [Yahoo! Finance]
Low
Report
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million [Yahoo! Finance]
3/5
04:05 pm
npce
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
High
Report
NeuroPace Announces Record Full Year 2023 Revenue of $65.4 Million
2/25
09:07 am
npce
NeuroPace: Picking Up The Pace [Seeking Alpha]
Medium
Report
NeuroPace: Picking Up The Pace [Seeking Alpha]
2/22
11:38 am
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Wells Fargo & Company from $9.00 to $16.00. They now have an "equal weight" rating on the stock.
Medium
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its price target raised by analysts at Wells Fargo & Company from $9.00 to $16.00. They now have an "equal weight" rating on the stock.
2/15
04:14 pm
npce
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 [Yahoo! Finance]
Low
Report
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024 [Yahoo! Finance]
2/15
04:05 pm
npce
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
Low
Report
NeuroPace to Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
2/7
03:25 am
npce
NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares [Yahoo! Finance]
Medium
Report
NeuroPace Inc Chief Medical Officer Martha Morrell Sells 17,589 Shares [Yahoo! Finance]
2/1
11:18 pm
npce
NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares [Yahoo! Finance]
Medium
Report
NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares [Yahoo! Finance]
1/31
06:18 am
npce
NeuroPace, Inc. (NASDAQ: NPCE) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Low
Report
NeuroPace, Inc. (NASDAQ: NPCE) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
1/30
08:12 am
npce
NeuroPace, Inc. (NASDAQ: NPCE) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $22.00 price target on the stock.
Low
Report
NeuroPace, Inc. (NASDAQ: NPCE) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $22.00 price target on the stock.